Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod
Biohaven Pharmaceutical Holding Co Ltd
said on Friday the U.S. health regulator failed to
approve its treatment for amyotrophic lateral sclerosis, or Lou
Gehrig's disease, sending its shares down nearly 6% in extended
trading.